Switching from efavirenz/tenofovir/emtricitabine (TDF/FTC/EFV) to abacavir/lamivudine/maraviroc (ABC/3TC/MVC) to assess antiretroviral activity in cerebrospinal fluid: a prospective one-arm pilot study.

Trial Profile

Switching from efavirenz/tenofovir/emtricitabine (TDF/FTC/EFV) to abacavir/lamivudine/maraviroc (ABC/3TC/MVC) to assess antiretroviral activity in cerebrospinal fluid: a prospective one-arm pilot study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Lamivudine/abacavir (Primary) ; Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MRVstudy-10 (XUMAKER); XUMAKER
  • Most Recent Events

    • 02 Apr 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 21 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top